Luveris PEN
Luveris PEN Uses, Dosage, Side Effects, Food Interaction and all others data.
Luveris PEN is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Luveris PEN was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. In males, LH stimulates Leydig cell to produce testosterone.
Used to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. Together they stimulate the development of a follicle to prepare the reproductive tract for implementation and pregnancy. Luveris PEN also stimulates the theca cells to produce androgens and the secretion of estradiol by the follicles. Luveris PEN and follitropin alfa are discontinued once ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation. hCG is then administered to complete follicular maturation and induce ovulation. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. Luveris PEN substitutes for endogenous LH and induces rupture of the preovulatory ovarian follicle and oocyte expulsion. Luveris PEN induces and maintains the corpus luteum, which then secretes progesterone.
| Trade Name | Luveris PEN |
| Generic | Lutropin alfa |
| Lutropin alfa Other Names | Lutropin alfa, Lutropin alpha, Lutropina alfa |
| Type | |
| Formula | C1014H1609N287O294S27 |
| Weight | 30000.0 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Merck |
| Available Country | Switzerland |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Luveris PEN is a form of recombinant human luteinizing hormone used to treat female infertility due to hypothalamic or pituitary insufficiency, or due to profound luteinizing hormone deficiency.
For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)
Luveris PEN is also used to associated treatment for these conditions: Hypogonadism, Infertility
How Luveris PEN works
Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.
Toxicity
Luveris PEN is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus.
Food Interaction
No interactions found.Volume of Distribution
The steady state volume of distribution is around 10-14 L.
Elimination Route
Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours
Half Life
Biphasic; terminal half-life is approximately 18 hours.
Clearance
- 2 – 3 L/h [healthy female following subcutaneous administration]
Elimination Route
Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.
Innovators Monograph
You find simplified version here Luveris PEN
